LOGILIA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Logilia, and what generic alternatives are available?
Logilia is a drug marketed by Teva Pharms Usa and is included in one NDA.
The generic ingredient in LOGILIA is ulipristal acetate. There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the ulipristal acetate profile page.
Summary for LOGILIA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | LOGILIA at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for LOGILIA
US Patents and Regulatory Information for LOGILIA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Usa | LOGILIA | ulipristal acetate | TABLET;ORAL | 207952-001 | Feb 13, 2017 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for LOGILIA
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Laboratoire HRA Pharma | ellaOne | ulipristal acetate | EMEA/H/C/001027 Emergency contraception within 120 hours (five days) of unprotected sexual intercourse or contraceptive failure. |
Authorised | no | no | no | 2009-05-15 | |
| Gedeon Richter Plc. | Ulipristal Acetate Gedeon Richter | ulipristal acetate | EMEA/H/C/005017 Ulipristal acetate is indicated for one treatment course of pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.Ulipristal acetate is indicated for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age who are not eligible for surgery. |
Withdrawn | no | no | no | 2018-08-27 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
